133 related articles for article (PubMed ID: 35971798)
1. New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index.
Terracciano D; La Civita E; Athanasiou A; Liotti A; Fiorenza M; Cennamo M; Crocetto F; Tennstedt P; Schiess R; Haese A; Ferro M; Steuber T
Prostate; 2022 Nov; 82(15):1469-1476. PubMed ID: 35971798
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Proclarix in the diagnostic work-up of prostate cancer.
Kaufmann B; Fischer S; Athanasiou A; Lautenbach N; Wittig A; Bieri U; Schmid FA; von Stauffenberg F; Scherer T; Eberli D; Gorin MA; Schiess R; Poyet C
BJUI Compass; 2024 Mar; 5(2):297-303. PubMed ID: 38371198
[TBL] [Abstract][Full Text] [Related]
3. PROPOSe: A Real-life Prospective Study of Proclarix, a Novel Blood-based Test to Support Challenging Biopsy Decision-making in Prostate Cancer.
Steuber T; Heidegger I; Kafka M; Roeder MA; Chun F; Preisser F; Palisaar RJ; Hanske J; Budaeus L; Schiess R; Keller T; Semjonow A; Hammerer P; Manka L; Ecke T; Schwentner C; Ohlmann C
Eur Urol Oncol; 2022 Jun; 5(3):321-327. PubMed ID: 33422560
[TBL] [Abstract][Full Text] [Related]
4. Proclarix, A New Biomarker for the Diagnosis of Clinically Significant Prostate Cancer: A Systematic Review.
Campistol M; Morote J; Regis L; Celma A; Planas J; Trilla E
Mol Diagn Ther; 2022 May; 26(3):273-281. PubMed ID: 35471698
[TBL] [Abstract][Full Text] [Related]
5. Relationship between Proclarix and the Aggressiveness of Prostate Cancer.
Campistol M; Triquell M; Regis L; Celma A; de Torres I; Semidey ME; Mast R; Mendez O; Planas J; Trilla E; Morote J
Mol Diagn Ther; 2023 Jul; 27(4):487-498. PubMed ID: 37081322
[TBL] [Abstract][Full Text] [Related]
6. Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging.
Morote J; Pye H; Campistol M; Celma A; Regis L; Semidey M; de Torres I; Mast R; Planas J; Santamaria A; Trilla E; Athanasiou A; Singh S; Heavey S; Stopka-Farooqui U; Freeman A; Haider A; Schiess R; Whitaker HC; Punwani S; Ahmed HU; Emberton M
BJU Int; 2023 Aug; 132(2):188-195. PubMed ID: 36855895
[TBL] [Abstract][Full Text] [Related]
7. Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?
Morote J; Campistol M; Regis L; Celma A; de Torres I; Semidey ME; Roche S; Mast R; Santamaria A; Planas J; Trilla E
Int J Biol Markers; 2022 Jun; 37(2):218-223. PubMed ID: 35200058
[TBL] [Abstract][Full Text] [Related]
8. Prostate Health Index density improves detection of clinically significant prostate cancer.
Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Mamawala M; Agostino J; Carter HB; Partin AW; Sokoll LJ; Ross AE
BJU Int; 2017 Dec; 120(6):793-798. PubMed ID: 28058757
[TBL] [Abstract][Full Text] [Related]
9. Serum (-2)proPSA/freePSAratio, (-2)proPSA/freePSA density, prostate health index, and prostate health index density as clues to reveal postoperative clinically significant prostate cancer in men with prostate-specific antigen 2-10 ng/mL.
Ferro M; Crocetto F; La Civita E; Fiorenza M; Jannuzzi G; Carbone G; Sirica R; Sicignano E; Pagano G; Imbimbo C; Terracciano D
Prostate; 2024 May; ():. PubMed ID: 38798011
[TBL] [Abstract][Full Text] [Related]
10. A Neural Network Model Combining [-2]proPSA, freePSA, Total PSA, Cathepsin D, and Thrombospondin-1 Showed Increased Accuracy in the Identification of Clinically Significant Prostate Cancer.
Gentile F; La Civita E; Ventura BD; Ferro M; Bruzzese D; Crocetto F; Tennstedt P; Steuber T; Velotta R; Terracciano D
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900150
[TBL] [Abstract][Full Text] [Related]
11. Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category.
Morote J; Campistol M; Triquell M; Celma A; Regis L; de Torres I; Semidey ME; Mast R; Santamaria A; Planas J; Trilla E
Eur Urol Open Sci; 2022 Mar; 37():38-44. PubMed ID: 35243388
[TBL] [Abstract][Full Text] [Related]
12. Prostate Health Index Density Outperforms Prostate Health Index in Clinically Significant Prostate Cancer Detection.
Chiu ST; Cheng YT; Pu YS; Lu YC; Hong JH; Chung SD; Chiang CH; Huang CY
Front Oncol; 2021; 11():772182. PubMed ID: 34869007
[TBL] [Abstract][Full Text] [Related]
13. Comparisons of the diagnostic accuracy across prostate health index, prostate health index density, and percentage free prostate-specific antigen for clinically significant prostate cancer: a prospective diagnostic study.
Wu B; Shao Y; Lin X; Hasi C; Jia W; Wang D; Cao X
Transl Androl Urol; 2023 Mar; 12(3):425-432. PubMed ID: 37032752
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy of Proclarix to Select Appropriate Candidates for Magnetic Resonance Imaging and Derived Prostate Biopsies in Men with Suspected Prostate Cancer.
Morote J; Campistol M; Celma A; Regis L; de Torres I; Semidey ME; Roche S; Mast R; Santamaría A; Planas J; Trilla E
World J Mens Health; 2022 Apr; 40(2):270-279. PubMed ID: 35021312
[TBL] [Abstract][Full Text] [Related]
15. The Prostate Health Index and multi-parametric MRI improve diagnostic accuracy of detecting prostate cancer in Asian populations.
Ye C; Ho JN; Kim DH; Song SH; Kim H; Lee H; Jeong SJ; Hong SK; Byun SS; Ahn H; Hwang SI; Lee HJ; Lee S
Investig Clin Urol; 2022 Nov; 63(6):631-638. PubMed ID: 36347552
[TBL] [Abstract][Full Text] [Related]
16. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy.
Cantiello F; Russo GI; Ferro M; Cicione A; Cimino S; Favilla V; Perdonà S; Bottero D; Terracciano D; De Cobelli O; Morgia G; Damiano R
Urol Oncol; 2015 Apr; 33(4):163.e15-23. PubMed ID: 25575715
[TBL] [Abstract][Full Text] [Related]
17. Do PHI and PHI density improve detection of clinically significant prostate cancer only in the PSA gray zone?
Rius Bilbao L; Valladares Gomez C; Aguirre Larracoechea U; Pereira Arias JG; Arredondo Calvo P; Urdaneta Salegui LF; Escobal Tamayo V; Sanz Jaka JP; Recio Ayesa A; Mar Medina J; Mar Medina C
Clin Chim Acta; 2023 Mar; 542():117270. PubMed ID: 36893880
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Prostate-Specific Antigen and Its Density and Prostate Health Index and Its Density for Detection of Prostate Cancer.
Boo Y; Chung JH; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Song W
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509551
[TBL] [Abstract][Full Text] [Related]
19. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
[TBL] [Abstract][Full Text] [Related]
20. The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center.
Cheng YT; Chiang CH; Pu YS; Liu SP; Lu YC; Chang YK; Chang HC; Huang KH; Lee YJ; Chow PM; Hung SC; Huang CY
J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):260-267. PubMed ID: 29779925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
